The FDA’s Oncologic Drugs Advisory Committee (ODAC) met on the morning of July 13th to discuss Biologics License Application (BLA) 761028.
The FDA’s Oncologic Drugs Advisory Committee (ODAC) met on the morning of July 13th to discuss Biologics License Application (BLA) 761028 for Amgen’s biosimilar to Genentech/Roche’s AVASTIN (bevacizumab), ABP 215. ABP 215’s proposed indications include: non-squamous non-small cell lung cancer, metastatic colorectal cancer, metastatic renal cell carcinoma, glioblastoma, and cervical cancer.
ABP 215 is a monoclonal antibody (MAB), which inhibits vascular endothelial growth factor (VEGF), thus blocking tumor angiogenesis. The sponsor presented results from their analytical similarity assessment, which included the establishment of primary structure, higher order structure and aggregate, impurities, and functional activity similarities between ABP 215 and the reference product, bevacizumab. The sponsor concluded that the results from the analytical similarity assessment demonstrated that ABP 215 was highly similar to bevacizumab. The sponsor then proceeded to present their findings on the non-clinical and clinical similarity assessments, which also resulted in ABP 215 demonstrating high pharmacological, pharmacokinetic (PK), as well as safety/efficacy profile similarity to bevacizumab. The sponsor concluded that ABP 215 will serve as a high-quality biosimilar, which will increase access to an important therapy for cancer patients.
The FDA presentation was largely supportive of the ABP 215 product and supported the sponsor’s claim that ABP 215 is an appropriate biosimilar to US-licensed bevacizumab. Additionally, the FDA supported that ABP 215 is scientifically justified to be extrapolated to all bevacizumab indications, due to analytical, non-clinical, and clinical similarity, which led to the conclusion of no meaningful differences between the two products. The FDA then posed several discussion questions and a voting question to the committee, regarding the similarity of ABP 215 to the reference product and extrapolation of ABP 215 to all proposed indications, currently held by the reference product. The committee was largely in agreement with the FDA and the vote resulted in a 17-0 positive outcome, supporting licensure of ABP 215 for all indications of US-licensed bevacizumab.
ISS has almost two decades of experience in developing regulatory strategies including support for FDA Advisory Committee meetings. We are involved in more FDA AdComms per year than even the largest pharmaceutical companies. For more information on how ISS can help you prepare for your next meeting, contact firstname.lastname@example.org.
Over the past few years, the number of ex-US manufacturers submitting a Class II exempt 510k device registration has increased substantially. For companies with medical devices that are approved and successful in a foreign market, the logical next step is to introduce their product into the US, which has one of the most lucrative healthcare markets in the world. Read more
FDA advisory committee meetings are important regulatory events for many manufacturers on the path to marketing approval. These meetings can quite literally result in the approval or rejection of a product based on the panel’s vote. Read more
One of the main challenges our clients face is determining which regulatory pathway is best for their products. For example, what if an OTC product has a Monograph active ingredient but that ingredient is present at a different amount than the permitted amount? Or what if the label claims a novel indication not specified in a Monograph? If you are debating pursuit of either regulatory pathway for your OTC drug, it is critical to consider cost, timeline, and label claims to ensure your products has a unique stance in today’s market. Read more
US distributors and agents trying to import rapid antibody tests for coronavirus face a number of obstacles. The good news is that FDA has opened up the Emergency Use Authorization (EUA) program to include SARS-CoV-2 (the virus) and COVID-19 (the disease), expediting time to market. Read more
The journey to scientific and commercial success is often complex and always critical, if you are looking for an expert partner to help steer you to confident solutions, contact us todayContact us